Prolia vs Tymlos
A side-by-side look at two bone health medications advertised on TV. Informational only — not medical advice.
| US Prolia | US Tymlos | |
|---|---|---|
| Generic name | denosumab | abaloparatide |
| Drug class | RANKL Inhibitor (Biologic) | PTHrP Analog (Bone-Building Agent) |
| Treats | Osteoporosis | Osteoporosis |
| Category | Bone Health | Bone Health |
| Manufacturer | Amgen | Radius Health |
| Year approved | 2010 | 2017 |
| FDA warning | Moderate warnings | Black box warning |
| Est. TV ad spend | $120M | — |
| Common side effects | Low blood calcium, Serious infections, Back and joint pain, Skin reactions | Dizziness, Nausea, Headache, Heart palpitations |
Frequently asked questions
Is Prolia or Tymlos better?
Neither is universally "better." Prolia (denosumab) and Tymlos (abaloparatide) are both used for bone health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Prolia and Tymlos?
Prolia is a RANKL Inhibitor (Biologic) made by Amgen, while Tymlos is a PTHrP Analog (Bone-Building Agent) made by Radius Health. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Prolia has the larger estimated TV advertising budget of the two.